Shionogi & Co., Ltd. (OTCMKTS:SGIOY) Short Interest Up 1,350.0% in June

Shionogi & Co., Ltd. (OTCMKTS:SGIOY) was the target of a significant growth in short interest in the month of June. As of June 30th, there was short interest totalling 2,900 shares, a growth of 1,350.0% from the June 15th total of 200 shares. Based on an average daily volume of 773,300 shares, the short-interest ratio is currently 0.0 days.

Shionogi & Co., Ltd. Stock Performance

Shares of OTCMKTS SGIOY traded up $0.11 during trading hours on Friday, hitting $10.48. 138,452 shares of the company’s stock were exchanged, compared to its average volume of 109,188. The company’s 50-day moving average price is $10.55 and its 200-day moving average price is $11.64. Shionogi & Co., Ltd. has a 1-year low of $9.33 and a 1-year high of $13.67. The stock has a market capitalization of $12.43 billion, a price-to-earnings ratio of 10.35, a PEG ratio of 2.80 and a beta of 0.21. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.86 and a quick ratio of 5.37.

Shionogi & Co., Ltd. (OTCMKTS:SGIOY) last posted its quarterly earnings data on Monday, May 13th. The company reported $0.21 earnings per share for the quarter. Shionogi & Co., Ltd. had a return on equity of 13.20% and a net margin of 37.29%. The company had revenue of $662.08 million during the quarter. On average, sell-side analysts expect that Shionogi & Co., Ltd. will post 0.87 earnings per share for the current fiscal year.

Shionogi & Co., Ltd. Company Profile

Shionogi & Co, Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug.